[Efficacy and Safety of Flumatinib and Imatinib as First-line Treatments for Newly-diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Real-world Study].
In real clinical practice, FM as first-line treatment achieves MMR earlier than IM, and exhibits good safety profile in newly-diagnosed CML-CP patients, which potentially leads to improved long-term survival and treatment-free remission.
Authors
- Hong Deng (ORCID: https://orcid.org/0000-0002-6343-2535)
- Xingli Zou (ORCID: https://orcid.org/0000-0002-1808-7031)
- Hongyan Wang (ORCID: https://orcid.org/0000-0003-2710-8698)
- Liang Zhang (ORCID: https://orcid.org/0000-0002-2279-2657)
- Meijiao Huang (ORCID: https://orcid.org/0000-0002-3486-4769)
- Tai-Ran Chen
- Yu Liu (ORCID: https://orcid.org/0000-0003-1337-2527)
Institutions
- North Sichuan Medical University (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.06.007
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article